## Daniella M Schwartz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3190460/publications.pdf

Version: 2024-02-01

22 papers 4,906 citations

430442 18 h-index 25 g-index

26 all docs

26 docs citations

26 times ranked 7112 citing authors

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annual Review of Medicine, 2015, 66, 311-328.   | 5.0  | 1,074     |
| 2  | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery, 2017, 16, 843-862.  | 21.5 | 759       |
| 3  | JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs, 2017, 77, 521-546.  | 4.9  | 711       |
| 4  | Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics, 2016, 48, 67-73.  | 9.4  | 513       |
| 5  | Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nature Reviews Rheumatology, 2016, 12, 25-36.   | 3.5  | 468       |
| 6  | A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Annals of the Rheumatic Diseases, 2018, 77, 728-735.                       | 0.5  | 176       |
| 7  | Orai1-Mediated Antimicrobial Secretion from Pancreatic Acini Shapes the Gut Microbiome and Regulates Gut Innate Immunity. Cell Metabolism, 2017, 25, 635-646.   | 7.2  | 127       |
| 8  | Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology, 2018, 104, 499-514.  | 1.5  | 122       |
| 9  | Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology, 2019, 58, i4-i16.  | 0.9  | 111       |
| 10 | JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. Journal of Allergy and Clinical Immunology, 2021, 148, 911-925.   | 1.5  | 57        |
| 11 | Retinoic Acid Receptor Alpha Represses a Th9 Transcriptional and Epigenomic Program to Reduce<br>Allergic Pathology. Immunity, 2019, 50, 106-120.e10.   | 6.6  | 54        |
| 12 | Targeting cytokine signaling in autoimmunity: back to the future and beyond. Current Opinion in Immunology, 2016, 43, 89-97.  | 2.4  | 47        |
| 13 | Editorial: Decernotinib: A Nextâ€Generation Jakinib. Arthritis and Rheumatology, 2016, 68, 31-34.   | 2.9  | 38        |
| 14 | Brief Report: Drugs Implicated in Systemic Autoimmunity Modulate Neutrophil Extracellular Trap Formation. Arthritis and Rheumatology, 2018, 70, 468-474.  | 2.9  | 34        |
| 15 | Ca2+ Influx Channel Inhibitor SARAF Protects Mice From Acute Pancreatitis. Gastroenterology, 2019, 157, 1660-1672.e2.   | 0.6  | 33        |
| 16 | Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20. Annals of the Rheumatic Diseases, 2020, 79, 429-431.  | 0.5  | 25        |
| 17 | Hyperlipidaemia and IFNgamma/TNFalpha Synergism are associated with cholesterol crystal formation in Endothelial cells partly through modulation of Lysosomal pH and Cholesterol homeostasis. EBioMedicine, 2020, 59, 102876. | 2.7  | 14        |
| 18 | Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features. Annals of the Rheumatic Diseases, 2021, 80, 788-795.                     | 0.5  | 12        |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations. Frontiers in Immunology, 2022, 13, 818039.                       | 2.2 | 8         |
| 20 | Oncogenes calling on a lysosomal Ca 2+ channel. EMBO Reports, 2019, 20, .   | 2.0 | 5         |
| 21 | STIM1 holds a STING in its (N-terminal) tail. Cell Calcium, 2019, 80, 192-193.  | 1.1 | 5         |
| 22 | Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific TÂcell therapy products. Molecular Therapy - Methods and Clinical Development, 2022, 25, 439-447. | 1.8 | 4         |